Pulmonary Fibrosis Biomarkers Market – By Test Type (Blood Test, Imaging Test, Lung Biopsy), Indication (Idiopathic Pulmonary Fibrosis, Pneumoconiosis, Sarcoidosis), End-user (Hospitals, Diagnostic Laboratories) – Global Forecast 2024 – 2032

Pulmonary Fibrosis Biomarkers Market Size

Pulmonary Fibrosis Biomarkers Market size was valued at around USD 4.1 billion in 2023 and is estimated to reach over USD 6 billion by 2032. Pulmonary fibrosis biomarkers are specific molecules, substances, or characteristics found in biological samples such as blood, sputum, or lung tissue that provide valuable information about the presence, severity, progression, or response to treatment of pulmonary fibrosis.
 

The increasing advancements in biomarker discovery technology is a significant driver for the market. For instance, according to the Prognostic Lung Fibrosis Consortium (PROLIFIC), in 2023, the identification of 12 potential prognostic, blood-based protein biomarkers helped predict the pulmonary fibrosis patient’s specific and selective requirement about the treatment regimen. This allows for the precision medicine approach and tailor treatment strategies to individuals based on their unique biomarker profiles.
 

Furthermore, market growth is attributed to multiple factors, including the rising prevalence of pulmonary fibrosis, growing government initiatives and policies, rising use of biomarkers, and increasing research and development in the multi-omics sector (which is estimated to reach 12.2 billion by 2032.

 

Pulmonary Fibrosis Biomarkers Market Trends

Market expansion is anticipated to be propelled by the rising prevalence of pulmonary fibrosis as it creates a greater need for biomarkers that can facilitate early detection and diagnosis.
 

• Biomarkers help in stratifying patients based on disease severity, prognosis, and response to treatment. This personalized approach ensures that patients receive appropriate and timely interventions, leading to better disease management.
   
• With a larger patient population, there is a need for more efficient clinical trials to test new therapies for pulmonary fibrosis. Consequently, biomarkers serve as endpoints, aiding in the evaluation of treatment efficacy and safety.
   
• Additionally, the rising disease prevalence leads to increased awareness among healthcare professionals and the general population. As, more patients are being screened for pulmonary fibrosis, these biomarkers offer a non-invasive or minimally invasive method for identifying individuals at risk.
   

Pulmonary Fibrosis Biomarkers Market Analysis

Based on test type, the market is segmented into blood test, pulmonary function test, imaging test, lung biopsy, and other test types. The imaging test segment held the market size of USD 1.7 billion in 2023.
 

• Patients with pulmonary fibrosis undergo periodic imaging tests to monitor disease progression and response to treatment. The findings are correlated with biomarker data to enhance understanding and accuracy in disease assessment. Consequently, the synergy between imaging and biomarkers drives the use of both modalities.
   
• Moreover, the advanced imaging tool, such as high-resolution computed tomography (HRCT) scan is the gold standard for diagnosing pulmonary fibrosis. It provides detailed images of lung structures, allowing for the identification of characteristic patterns of fibrosis.
   
• Additionally, imaging tests complement biomarker analysis, providing a comprehensive view of disease status. Thus, their role in diagnosis, disease monitoring, treatment planning, and research makes them essential tools in the management of pulmonary fibrosis.
   

Based on indication, the pulmonary fibrosis biomarkers market is segmented into idiopathic pulmonary fibrosis (IPF), rheumatoid arthritis interstitial lung disease (RA-ILD), drug-induced pulmonary fibrosis, COVID-19-related pulmonary fibrosis, pneumoconiosis, sarcoidosis, and other indications. The idiopathic pulmonary fibrosis (IPF) segment is expected reach a market size of USD 2.1 billion by 2032.
 

• Idiopathic pulmonary fibrosis (IPF) is the most common and well-known form of idiopathic interstitial pneumonia, accounting for a significant proportion of interstitial lung diseases. For instance, according to the National Library of Medicine, IPF has an estimated prevalence of 13 to 20 per 1,00,000 people worldwide. About 1,00,000 people are affected in the U.S., and 30,000 to 40,000 new cases are diagnosed each year.
   
• Biomarkers such as MMP-7, SP-A, and cytokines IL-6, TGF-β) are associated with disease severity and prognosis. Data from them provide insights into disease activity and treatment response for idiopathic pulmonary fibrosis.
   

Based on end-user, the pulmonary fibrosis biomarkers market is classified into hospitals, specialty clinics, diagnostic laboratories, research & academic institutes, and other end-users. The hospitals segment held a market share of 33.4% in the year 2023.
 

• Hospitals play a central role in managing pulmonary fibrosis patients. As, biomarkers are used for monitoring disease progression, treatment response, and overall patient care under one roof.
   
• Additionally, many hospitals have specialized laboratories equipped for biomarker testing, with pulmonologists, radiologists, and pathologists working together. Consequently, biomarkers are utilized by these teams for collaborative decision-making in patient management.
   
• For instance, according to the National Library of Medicine, in 2021, in-hospital mortality rates among patients with IPF have been reported to be approximately 13% to 15%. Thus, hospitals with specialized pulmonary fibrosis programs and experienced care teams helps to reduce the mortality rates, thereby influencing the market growth.
   

North America pulmonary fibrosis biomarkers market accounted for USD 1.7 billion revenue in 2023 and is predicted to witness substantial market growth over the analysis timeline.
 

• The significant market share is correlated to a highly advanced healthcare infrastructure with well-established hospitals, research institutions, and diagnostic laboratories. This infrastructure enables the widespread adoption of biomarker testing for pulmonary fibrosis.
   
• North America has a relatively high prevalence of pulmonary fibrosis, a chronic and progressive lung disease. For instance, according to the American Lung Association, in 2023, around 33.8 million adults were being diagnosed with chronic lung disease.
   
• There is a growing awareness of pulmonary fibrosis among healthcare professionals and the general population in region. Early diagnosis and monitoring of the disease are crucial for better patient outcomes, leading to increased adoption of biomarker testing.
   

Pulmonary Fibrosis Biomarkers Market Share

The pulmonary fibrosis biomarkers industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. Companies are developing innovative biomarkers to aid in disease diagnosis, prognosis, and treatment monitoring. These biomarkers range from genetic markers to protein expression profiles, reflecting the complex nature of pulmonary fibrosis. Key factors driving competitiveness include the accuracy, specificity, and reproducibility of biomarkers, as well as their potential to guide personalized treatment strategies. Regulatory approvals and collaborations with research institutions further influence market positioning.
 

Pulmonary Fibrosis Biomarkers Market Companies

Some of the eminent market participants operating in the pulmonary fibrosis biomarkers industry include:

• Biocartis NV
• Biogen Inc
• Bristol-Myers Squibb Company
• F. Hoffman-La Roche Ltd
• Galapagos NV
• Lung Therapeutics, Inc.
• Myriad Genetics, Inc
• OptiKira LLC
• Respivant Sciences GmbH
• Veracyte, Inc
   

Pulmonary Fibrosis Biomarkers Industry News:

• In October 2023, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for BMS-986278, a first-in-class, oral, lysophosphatidic acid receptor 1 (LPA1) antagonist, for the treatment of progressive pulmonary fibrosis (PPF), a devastating, life-threatening illness. Thus, it increased the product portfolio of the company.
   
• In March 2020, Bristol Myers Squibb announced a collaboration with the Pulmonary Fibrosis Foundation (PFF) to identify biomarkers. This partnership aimed to accelerate the development of targeted treatments for this challenging condition, emphasizing the company's dedication to improving patient outcomes, thereby increased the sales and generated revenue.
   

Pulmonary fibrosis biomarkers market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Test Type

• Blood test
  • C-reactive protein test
  • Antibody testing kits
    • Antinuclear antibodies (ANA) test
    • Anti-CCP antibody test
  • ESR test and CBC 
• Pulmonary function test
• Imaging test
  • X-rays scans
  • HRCT scans
• Lung biopsy
• Other test types

Market, By Indication

• Idiopathic pulmonary fibrosis (IPF)
• Rheumatoid arthritis interstitial lung disease (RA-ILD)
• Drug-induced pulmonary fibrosis
• COVID-19-related pulmonary fibrosis
• Pneumoconiosis
• Sarcoidosis
• Other indications

Market, By End-user

• Hospitals
• Specialty clinics
• Diagnostic laboratories
• Research & academic institutes
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa